Dr. Brigette Roberts is Chief Executive Officer and a member of the Board of Directors at OrphAI Therapeutics, a clinical‑stage biopharmaceutical company harnessing its Guardian Angel™ deep‑learning platform to create first‑ and best‑in‑class treatments for rare, life‑threatening diseases. She has guided the organization’s evolution and, in September 2023, led its re‑branding from AI Therapeutics to OrphAI Therapeutics to reflect a broadened, multi‑asset pipeline and sharpened orphan‑disease focus. Since assuming leadership May 2021, Dr. Roberts has secured more than $30 million in new private investment. She has advanced AIT‑101, a first‑in‑class PIKfyve inhibitor, through a Phase 2a trial in C9orf72‑ALS and, under her direction, the candidate earned U.S. and EU orphan‑drug designations. In the pulmonary franchise, she has initiated two Phase 2 studies of LAM‑001, an inhaled formulation of rapamycin. Before joining OrphAI, Dr. Roberts spent 15 years as a healthcare investor and portfolio manager at Third Point, CDP Capital, Angel Lane Principal Strategies and DKR Capital, and founded her own long/short healthcare fund, YYC Capital. Her activist work included a board seat at Ligand Pharmaceuticals. Her investing success earned her a place on Fortune’s “40 Under 40: Ones to Watch” list and recognition in Business Insider for running a top‑performing fund while still in her thirties. Dr. Roberts earned her B.A. in Physics & Chemistry from Harvard and her M.D. from New York University before transitioning to finance and entrepreneurship. Combining rigorous scientific training and public‑markets insight, Dr. Roberts directs OrphAI Therapeutics’ strategy to deliver disease‑altering therapies to underserved patients worldwide while building long‑term value for stakeholders.
